Nuvalent Sees Unusually Large Options Volume (NASDAQ:NUVL)

Nuvalent, Inc. (NASDAQ:NUVL) was the target of some unusual options trading activity on Tuesday. Stock investors bought 5,384 call options on the company. This is an increase of approximately 9,870% compared to the average volume of 54 call options.

Wall Street Analyst Weigh In

A number of analysts have commented on NUVL shares. TD Cowen cut shares of Nuvalent from a “buy” rating to a “hold” rating in a research report on Tuesday. Raymond James Financial cut shares of Nuvalent from an “outperform” rating to a “market perform” rating in a research report on Tuesday. Cantor Fitzgerald cut shares of Nuvalent from an “overweight” rating to a “neutral” rating in a research report on Tuesday. Piper Sandler cut shares of Nuvalent from an “overweight” rating to a “neutral” rating and set a $124.00 price objective on the stock. in a research report on Tuesday. Finally, Robert W. Baird set a $122.85 price objective on shares of Nuvalent in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Nuvalent has a consensus rating of “Moderate Buy” and a consensus price target of $133.71.

Insider Activity

In other Nuvalent news, insider Henry E. Pelish sold 3,093 shares of the company’s stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $104.48, for a total transaction of $323,156.64. Following the sale, the insider owned 65,604 shares of the company’s stock, valued at approximately $6,854,305.92. This represents a 4.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Deborah Ann Miller sold 5,500 shares of the company’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $107.84, for a total transaction of $593,120.00. Following the sale, the insider directly owned 59,634 shares in the company, valued at $6,430,930.56. This trade represents a 8.44% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 96,953 shares of company stock worth $9,956,364. 5.02% of the stock is owned by insiders.

Hedge Funds Weigh In On Nuvalent

A number of institutional investors and hedge funds have recently made changes to their positions in NUVL. RA Capital Management L.P. bought a new position in Nuvalent in the 3rd quarter valued at about $107,794,000. Wellington Management Group LLP lifted its position in Nuvalent by 46.0% in the 3rd quarter. Wellington Management Group LLP now owns 2,300,865 shares of the company’s stock valued at $198,979,000 after acquiring an additional 724,491 shares in the last quarter. Vanguard Group Inc. lifted its position in Nuvalent by 13.9% in the 4th quarter. Vanguard Group Inc. now owns 5,244,271 shares of the company’s stock valued at $527,521,000 after acquiring an additional 639,264 shares in the last quarter. Norges Bank bought a new position in Nuvalent in the 4th quarter valued at about $57,763,000. Finally, JPMorgan Chase & Co. lifted its position in Nuvalent by 32.9% in the 4th quarter. JPMorgan Chase & Co. now owns 2,205,251 shares of the company’s stock valued at $221,826,000 after acquiring an additional 545,542 shares in the last quarter. Institutional investors own 97.26% of the company’s stock.

Nuvalent Price Performance

NUVL stock opened at $123.25 on Wednesday. The stock has a market capitalization of $9.74 billion, a PE ratio of -20.34 and a beta of 1.15. The company’s 50-day moving average is $102.91 and its 200-day moving average is $103.08. Nuvalent has a 1 year low of $71.13 and a 1 year high of $123.62.

Nuvalent (NASDAQ:NUVL) last released its quarterly earnings data on Thursday, May 7th. The company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.04). During the same period in the prior year, the company earned ($1.18) EPS. On average, analysts anticipate that Nuvalent will post -5.74 earnings per share for the current fiscal year.

Key Headlines Impacting Nuvalent

Here are the key news stories impacting Nuvalent this week:

• Positive Sentiment: GSK announced a definitive all-cash acquisition of Nuvalent for about $10.6 billion, giving shareholders $124 per share and sparking a takeover-driven rerating. Reuters article
• Positive Sentiment: The deal adds Nuvalent’s late-stage lung cancer pipeline to GSK’s oncology business, which likely helped justify the premium and support investor enthusiasm. WSJ article
• Positive Sentiment: Options activity surged sharply, suggesting traders were positioning for further upside and volatility around the buyout news. Quiver Quant article
• Neutral Sentiment: Several analysts adjusted ratings and price targets to around the deal value, which reflects the market now focusing more on the acquisition price than standalone fundamentals. Benzinga article
• Negative Sentiment: Law firms and investor groups launched investigations into whether shareholders are receiving a fair price, adding a layer of deal-related uncertainty. GlobeNewswire article
• Negative Sentiment: Recent analyst downgrades to neutral could temper expectations for any upside beyond the takeover price. Benzinga article

About Nuvalent

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.